Φαρμακευτικο Μαρκετινγκ: Θεωρια, Πρακτικη, Δεοντολογια

The ultimate guide for Pharma Marketing Champions

Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…

http://www.stamoulis.gr/ViewShopProduct.aspx?ProductId=402023

Σε κίνδυνο η βιωσιμότητα των φαρμακευτικών εταιριών

Ο διευθύνων σύμβουλος της Genesis Pharma, Κωνσταντίνος Ευριπίδης σε συνέντευξη του στην εφημερίδα «Ημερησία του Σαββάτου» επισημαίνει ότι απειλείται η βιωσιμότητα των φαρμακευτικών εταιριών που λειτουργούν στην Ελλάδα. Όπως υποστηρίζει ότι το καίριο πλήγμα στον κλάδο ήρθε από το «κούρεμα» των ομολόγων για την απομείωση του ελληνικού χρέους, με αποτέλεσμα να πλήττεται η βιωσιμότητα επιχειρήσεων που μέχρι πρότινος ήταν απολύτως υγιείς.

Το πλήρες κείμενο της συνέντευξης στον δημοσιογράφο Γιώργο Μανέττα έχει ως εξής:

FDA panel recommends approval of drug to prevent HIV infection

The Washington Post | By  Brian Vastag   

For the first time in the 30-year battle against the HIV epidemic, a panel of experts has recommended that the Food and Drug Administration approve a drug to give to healthy people to protect against the infection.

The panel recommended Thursday that the agency approve the drug Truvada for preventing HIV in men who have sex with men, HIV-negative partners of HIV-postive people and “other individuals at risk for acquiring HIV through sexual activity.” 

The FDA is considering the use of Truvada for healthy people to prevent the contraction of HIV. Dr. Jon LaPook reports on the revolutionary prevention pill. The FDA usually follows the advice of its advisory committees, which are made up of experts from outside the agency, although it does not have to. Its decision is expected by June 15.

Switching Rx drugs to OTC and adding comparative data could broaden access to treatment

 PharmExec | Jill Wechsler 

Great enthusiasm for personalized and patient-centered medicine is driving a host of innovative regulatory and research proposals. The Food and Drug Administration is seeking to promote informed self-treatment by switching some current Rx drugs to OTC status with additional “conditions for safe use.” Government support for Comparative Effectiveness Research (CER) offers new opportunities for researchers, payers, and pharma companies to identify optimal treatments for a broad range of medical conditions. The clamor for more information on drug use and effects in such “real world” situations is shaping clinical research and coverage decisions. 

Physician gift tracking by drug companies delayed until 2013

amednews | By Charles Fiegl

Proposed transparency rules need further revision and clarification to ensure accuracy of the reporting process, according to the Centers for Medicare & Medicaid Services.

Federal requirements for collecting information on gifts and payments to physicians from drug and device manufacturers will not begin until 2013, said a top Centers for Medicare & Medicaid Services official.